Cardiac [beta]-adrenoceptor expression is reduced in zucker diabetic fatty rats as type-2 diabetes progresses

Reduced cardiac [beta]-adrenoceptor ([beta]-AR) expression and cardiovascular dysfunction occur in models of hyperglycemia and hypoinsulinemia. Cardiac [beta]-AR expression in type-2 diabetes models of hyperglycemia and hyperinsulinemia, remain less clear. This study investigates cardiac [beta]-AR expression in type-2 diabetic Zucker diabetic fatty (ZDF) rats. Ex vivo biodistribution experiments with [.sup.3 H]CGP12177 were performed in Zucker lean (ZL) and ZDF rats at 10 and 16 weeks of age as diabetes develops. Blood glucose, body mass, and diet consumption were measured. Western blotting of [beta]-AR subtypes was completed in parallel. Echocardiography was performed at 10 and 16 weeks to assess systolic and diastolic function. Fasted plasma insulin, free fatty acids (FFA), leptin and fed-state insulin were also measured. At 10 weeks, myocardial [.sup.3 H]CGP12177 was normal in hyperglycemic ZDF (17±4.1mM) compared to ZL, but reduced 16-25% at 16 weeks of age as diabetes and hyperglycemia (22±2.4mM) progressed. Reduced [beta]-AR expression not apparent at 10 weeks also developed by 16 weeks of age in ZDF brown adipose tissue. In the heart, Western blotting at 10 weeks indicated normal [beta].sub.1 -AR (98±9%), reduced [beta].sub.2 -AR (76±10%), and elevated [beta].sub.3 -AR (108±6). At 16 weeks, [beta].sub.1 -AR expression became reduced (69±16%), [beta].sub.2 -AR expression decreased further (68±14%), and [beta].sub.3 -AR remained elevated, similar to 10 weeks (112±9%). While HR was reduced at 10 and 16 weeks in ZDF rats, no significant changes were observed in diastolic or systolic function. Cardiac [beta]-AR are reduced over 6 weeks of sustained hyperglycemia in type-2 diabetic ZDF rats. This indicates cardiac [.sup.3 H]CGP12177 retention and [beta].sub.1 - and [beta].sub.2 -AR expression are inversely correlated with the progression of type-2 diabetes.